The ability of cancer cells to activate and upregulate any program of drug resistance which involves increased expression of proteins (e.g. drug efflux transporters) necessitates active protein translation and therefore PI3K/AKT/mTOR pathway engagement. This evidence concerns the gene AKT1 and cancer.